S
2.07
+6.15%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$81.2m
FY2019FY2025
Net income
−$27.2m
FY2019FY2025
Free cash flow
−$1.2m
FY2019FY2025
Shareholders' equity
−$16.4m
FY2019FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $81.2m | $84.5m | $60.9m | $74.4m | $106.7m | $124.9m | $86.3m |
| Gross profit | $22.2m | $30.2m | $12.2m | $21.3m | $43.0m | $57.6m | $8.2m |
| Research and development | $14,600 | $11.6m | $5.1m | $3.0m | $834,818 | $1.4m | $2.0m |
| Operating income | −$15.7m | $3.9m | −$10.5m | −$1.6m | $8.3m | $30.0m | −$16.7m |
| Net income | −$27.2m | $1.8m | −$9.1m | $947,807 | $8.5m | $30.7m | −$13.9m |
| Diluted earnings per share | -3.59 | 0.25 | -0.25 | 0.13 | 1.15 | 3.60 | -1.64 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Total assets | $81.1m | $62.2m | $90.9m | $72.8m | $80.1m | $123.6m | $114.4m |
| Cash and short-term investments | $8.76bn | $7.3m | $15.2m | $13.9m | $10.2m | $27.6m | $3.7m |
| Total liabilities | $103.0m | $58.0m | $88.1m | $63.4m | $70.0m | $89.3m | $83.7m |
| Debt | $19.2m | $7.2m | $14.9m | $22.0m | $18.6m | $18.0m | $27.8m |
| Shareholders' equity | −$16.4m | $9.7m | $8.3m | $14.9m | $15.6m | $39.4m | $30.7m |
| Shares outstanding | 8m | 7m | 37m | 7m | 7m | 9m | 9m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | −$1.2m | −$1.6m | $465,868 | −$3.4m | $15.8m | $48.5m | $55.2m |
| Capital spending | −$15,794 | −$4 | −$2 | −$5,256 | −$5.0m | −$32,822 | −$5.4m |
| Free cash flow | −$1.2m | −$1.6m | $465,866 | −$3.4m | $10.8m | $48.5m | $49.8m |
| Dividends paid | — | — | — | −$8.2m | — | — | — |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.7m | $27.3m | $25.1m | $13.8m | $22.2m | $20.1m | $26.2m | $22.5m |
| Gross profit | $7.7m | $11.7m | $9.6m | $14,406 | $7.0m | $5.8m | $11.3m | $8.7m |
| Operating income | −$3.0m | $2.3m | −$710,449 | −$9.5m | −$2.5m | −$4.1m | $3.0m | $406,861 |
| Net income | −$3.0m | $2.1m | −$862,154 | −$7.9m | −$16.6m | −$1.9m | $1.1m | $235,147 |
| Diluted earnings per share | -0.36 | 0.25 | -0.11 | -1.04 | -2.18 | -0.26 | 0.15 | 0.03 |
| Cash from operations | −$3.0m | $10.0m | −$5.0m | $6.0m | −$3.0m | — | −$3.0m | −$4.0m |
| Capital spending | — | — | — | −$1.0m | — | −$1.0m | — | — |
| Free cash flow | — | — | — | $5.0m | — | — | — | — |
| Total assets | $57.1m | $56.8m | $59.3m | $51.1m | $58.0m | $64.5m | $62.2m | $66.8m |
| Cash and short-term investments | $13.86trn | $14.4m | $8.6m | $12.3m | $7.9m | $9.4m | $7.3m | $10.6m |
| Debt | $8.5m | $10.6m | $14.8m | $10.8m | $12.2m | $9.6m | $7.2m | $7.4m |
| Shareholders' equity | −$11.5m | −$14.2m | −$16.4m | −$15.6m | −$8.0m | $9.1m | $9.7m | $8.2m |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 3.1% | -8.3% | — |
| Operating income | 113.7% | — | — |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 31.6% | 28.5% | 35.0% | — |
| Operating margin | -7.1% | -7.9% | 2.7% | — |
| Net margin | -15.3% | -11.1% | 1.1% | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Price to earnings | -0.6 | 19.2 | -12.5 | 29.2 |
| Price to sales | 0.2 | 0.4 | 1.9 | 0.4 |
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Return | -47% | 43% | -18% | -36% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 5-to-1 reverse split · 6 Jul 2026
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.